Eli Lilly (LLY) secures position in India’s obesity drug market ahead of generic competition. India projected to have second-largest overweight population by 2050. Eli Lilly’s Mounjaro becomes top-selling therapy in India. Company cuts prices of diabetes and weight-loss drugs in Canada and US. Eli Lilly focuses on diabetes, oncology, immunology, and neuroscience. No promotional content included.

Read more at Yahoo Finance: Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market